Valentina Fogal
Overview
Explore the profile of Valentina Fogal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
837
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fogal V, Michopoulos F, Jarnuczak A, Hamza G, Harlfinger S, Davey P, et al.
Arch Toxicol
. 2024 May;
98(8):2589-2603.
PMID: 38755480
The tumour suppressor p16/CDKN2A and the metabolic gene, methyl-thio-adenosine phosphorylase (MTAP), are frequently co-deleted in some of the most aggressive and currently untreatable cancers. Cells with MTAP deletion are vulnerable...
2.
Yenugonda V, Nomura N, Kouznetsova V, Tsigelny I, Fogal V, Nurmemmedov E, et al.
J Transl Med
. 2017 Oct;
15(1):210.
PMID: 29047383
Background: The mitochondrial protein p32 is a validated therapeutic target of cancer overexpressed in glioma. Therapeutic targeting of p32 with monoclonal antibody or p32-binding LyP-1 tumor-homing peptide can limit tumor...
3.
Fogal V, Richardson A, Karmali P, Scheffler I, Smith J, Ruoslahti E
Mol Cell Biol
. 2017 Jul;
37(14).
PMID: 28663271
No abstract available.
4.
Fogal V, Babic I, Chao Y, Pastorino S, Mukthavaram R, Jiang P, et al.
Oncotarget
. 2014 Dec;
6(2):1157-70.
PMID: 25528767
Metabolic reprogramming is a key feature of tumorigenesis that is controlled by oncogenes. Enhanced utilization of glucose and glutamine are the best-established hallmarks of tumor metabolism. The oncogene c-Myc is...
5.
Jiang P, Mukthavaram R, Mukthavavam R, Chao Y, Bharati I, Fogal V, et al.
J Transl Med
. 2014 Jan;
12:13.
PMID: 24433351
Background: Glioblastoma (GBM) is a therapeutic challenge, associated with high mortality. More effective GBM therapeutic options are urgently needed. Hence, we screened a large multi-class drug panel comprising the NIH...
6.
Mukthavaram R, Jiang P, Saklecha R, Simberg D, Bharati I, Nomura N, et al.
Int J Nanomedicine
. 2013 Nov;
8:3991-4006.
PMID: 24174874
Staurosporine (STS) is a potent pan-kinase inhibitor with marked activity against several chemotherapy-resistant tumor types in vitro. The translational progress of this compound has been hindered by poor pharmacokinetics and...
7.
Ren Y, Cheung H, von Maltzhan G, Agrawal A, Cowley G, Weir B, et al.
Sci Transl Med
. 2012 Aug;
4(147):147ra112.
PMID: 22896676
The comprehensive characterization of a large number of cancer genomes will eventually lead to a compendium of genetic alterations in specific cancers. Unfortunately, the number and complexity of identified alterations...
8.
Hamzah J, Kotamraju V, Seo J, Agemy L, Fogal V, Mahakian L, et al.
Proc Natl Acad Sci U S A
. 2011 Apr;
108(17):7154-9.
PMID: 21482787
The ability to selectively deliver compounds into atherosclerotic plaques would greatly benefit the detection and treatment of atherosclerotic disease. We describe such a delivery system based on a 9-amino acid...
9.
Sanchez-Martin D, Cuesta A, Fogal V, Ruoslahti E, Alvarez-Vallina L
J Biol Chem
. 2010 Dec;
286(7):5197-203.
PMID: 21156793
Tumor-associated cell surface antigens and tumor-associated vascular markers have been used as a target for cancer intervention strategies. However, both types of targets have limitations due to accessibility, low and/or...
10.
Fogal V, Richardson A, Karmali P, Scheffler I, Smith J, Ruoslahti E
Mol Cell Biol
. 2010 Jan;
30(6):1303-18.
PMID: 20100866
p32/gC1qR/C1QBP/HABP1 is a mitochondrial/cell surface protein overexpressed in certain cancer cells. Here we show that knocking down p32 expression in human cancer cells strongly shifts their metabolism from oxidative phosphorylation...